Fluorouracil

證據等級: L5

預測適應症: 10 個

Fluorouracil: From Antineoplastic Chemotherapy to Botryoid-Type Embryonal Rhabdomyosarcoma of the Vagina

One-Sentence Summary

Fluorouracil (5-FU) is a pyrimidine-analogue antimetabolite used broadly in cytotoxic chemotherapy; no confirmed original indication or Taiwan marketing data is available in this evidence pack. The TxGNN model predicts it may be effective for botryoid-type embryonal rhabdomyosarcoma of the vagina, but this is an ultra-rare disease subtype with zero clinical trials and zero publications currently supporting the specific prediction — the score reflects TxGNN’s disease-ontology similarity only, not real-world evidence.

Quick Overview

Item	Content
Original Indication	Not available (no Taiwan license or original-indication data on file)
Predicted New Indication	Botryoid-type embryonal rhabdomyosarcoma of the vagina
TxGNN Prediction Score	99.75%
Evidence Level	L5
US Market Status	未上市 (Not Marketed)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap). Based on the repurposing rationale accompanying this candidate, fluorouracil is a pyrimidine analogue that inhibits thymidylate synthase, blocking DNA synthesis and producing broad cytotoxicity against rapidly dividing cells — a mechanism consistent with its known role as a general-purpose cytotoxic chemotherapy agent.

The predicted link to this specific rhabdomyosarcoma (RMS) subtype is inferred purely from disease-ontology similarity to other RMS subtypes in the TxGNN knowledge graph, not from any direct study of this histology. A related, more general candidate in the same evidence pack — “rhabdomyosarcoma (disease)” — does have some supporting literature on cytotoxic chemotherapy in pediatric sarcomas, but 5-FU is not part of the standard RMS regimen (VAC: vincristine/actinomycin-D/cyclophosphamide), and none of that literature addresses the vaginal botryoid subtype specifically. For this exact indication, the mechanistic rationale remains theoretical only.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

US Market Information

No marketing authorizations on file — Taiwan regulatory status is “未上市” (not marketed) with 0 registered licenses.

Cytotoxicity

Fluorouracil is a conventional cytotoxic chemotherapy agent (fluoropyrimidine/antimetabolite class), so this section applies.

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (fluoropyrimidine/antimetabolite class; thymidylate synthase inhibition)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: This candidate has no clinical trials, no literature, and no Taiwan regulatory footprint — the 99.75% score reflects TxGNN disease-similarity to other rhabdomyosarcoma subtypes, not actual evidence for this ultra-rare histology. Evidence Level L5 (model prediction only) does not support any advancement decision at this time.

To proceed, the following is needed:

TFDA package insert warnings/contraindications (blocking data gap — requires downloading and parsing the label PDF)
Confirmed mechanism of action from DrugBank API (currently missing)
Preclinical or case-level evidence specific to botryoid-type embryonal RMS of the vagina before this candidate can move past S0

Note on related candidates in this evidence pack: two other predicted indications for fluorouracil carry materially stronger evidence and may warrant separate evaluation — “rhabdomyosarcoma (disease)” (L4, 5 literature citations) and “liver sarcoma” (L3, 6 trials + 20 publications, though most trials matched on keyword rather than direct relevance to primary liver sarcoma). Neither reaches Go-level evidence, but both are better starting points than this specific vaginal-subtype candidate.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.